{"organizations": [], "uuid": "85b4d21257a3271019c17cdb463d4c192952b9aa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/07/28/pfizer-results-idUSL3N1083XL20150728", "country": "US", "title": "UPDATE 1-Pfizer's revenue, profit beat as vaccine sales rise", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "UPDATE 1-Pfizer's revenue, profit beat as vaccine sales rise | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-07-28T16:03:00.000+03:00", "replies_count": 0, "uuid": "85b4d21257a3271019c17cdb463d4c192952b9aa"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/07/28/pfizer-results-idUSL3N1083XL20150728", "ord_in_thread": 0, "title": "UPDATE 1-Pfizer's revenue, profit beat as vaccine sales rise", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details, estimates, shares)\nJuly 28 (Reuters) - Pfizer Inc reported better-than-expected quarterly profit and revenue, helped by strong demand for its pneumonia vaccine Prevnar 13 and sales of its breast cancer drug, Ibrance.\nThe company, which also raised its full-year adjusted earnings forecast, said revenue from its global vaccines unit rose 44 percent to $1.58 billion. The unit accounted for about 13 percent of Pfizer's total revenue.\nIbrance, approved by the U.S. Food and Drug Administration in February, generated $140 million in revenue in the second quarter.\nPfizer's shares rose about 2 percent in premarket trading on Tuesday.\nThe drugmaker raised its adjusted profit forecast for 2015 to $2.01-$2.07 per share from $1.95-$2.05.\nIt increased the lower end of its revenue forecast to $45 billion from $44 billion, maintaining the upper end at $46 billion.\nPfizer, which got nearly two-thirds of its 2014 revenue from markets outside the United States, had cut its full-year revenue and profit forecast in April, citing a strong dollar.\nThe company's net income fell to $2.63 billion, or 42 cents per share, in the second quarter from $2.91 billion, or 45 cents per share, a year earlier.\nExcluding items, Pfizer earned 56 cents per share.\nRevenue fell 7 percent to $11.85 billion, hurt by a stronger dollar.\nAnalysts on average had expected a profit of 52 cents per share and revenue of $11.42 billion, according to the Thomson Reuters I/B/E/S.\nPfizer's shares were trading at $34.93 before the bell. The stock had risen 7 percent in the six months to June 30. (Reporting by Ankur Banerjee in Bengaluru; Editing by Simon Jennings and Kirti Pandey)", "external_links": [], "published": "2015-07-28T16:03:00.000+03:00", "crawled": "2015-07-28T15:12:53.441+03:00", "highlightTitle": ""}